TG Therapeutics (NASDAQ:TGTX) Stock Rating Reaffirmed by JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their overweight rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research report report published on Thursday morning, Benzinga reports. They currently have a $25.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on TGTX. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a neutral rating in a report on Thursday, February 29th. HC Wainwright reaffirmed a buy rating and issued a $45.00 target price on shares of TG Therapeutics in a research note on Thursday. StockNews.com cut TG Therapeutics from a buy rating to a hold rating in a report on Saturday, February 24th. Finally, B. Riley increased their target price on TG Therapeutics from $24.00 to $29.00 and gave the stock a buy rating in a report on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $29.00.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $13.99 on Thursday. TG Therapeutics has a 12-month low of $6.46 and a 12-month high of $35.67. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of 699.85 and a beta of 2.30. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The firm has a fifty day moving average of $15.13 and a 200-day moving average of $13.87.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The company had revenue of $43.97 million during the quarter, compared to analyst estimates of $40.06 million. During the same quarter in the previous year, the business earned ($0.39) EPS. On average, equities research analysts forecast that TG Therapeutics will post -0.12 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the transaction, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of TG Therapeutics by 13.3% during the 3rd quarter. Vanguard Group Inc. now owns 14,746,392 shares of the biopharmaceutical company’s stock worth $87,299,000 after buying an additional 1,725,560 shares during the last quarter. State Street Corp boosted its stake in shares of TG Therapeutics by 47.8% during the 2nd quarter. State Street Corp now owns 14,235,263 shares of the biopharmaceutical company’s stock worth $60,500,000 after buying an additional 4,606,679 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in shares of TG Therapeutics during the 1st quarter worth about $157,187,000. BlackRock Inc. boosted its stake in shares of TG Therapeutics by 12.1% during the 2nd quarter. BlackRock Inc. now owns 9,917,463 shares of the biopharmaceutical company’s stock worth $246,350,000 after buying an additional 1,067,763 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in TG Therapeutics by 1.4% in the 4th quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock valued at $53,627,000 after purchasing an additional 43,290 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.